Dimdazenil: Difference between revisions

Edit links
From Wikipedia, the free encyclopedia
Browse history interactively
← Previous editNext edit →
Content deleted Content added
VisualWikitext
Adding short description: "Chemical compound"
merge from EVT-201
Line 52: Line 52:
| CAS_number = 308239-86-3
| CAS_number = 308239-86-3
| UNII = 6J8AF7CLE4
| UNII = 6J8AF7CLE4
| UNII_Ref = {{fdacite|correct|FDA}}
| PubChem = 9885841
| PubChem = 9885841
| DrugBank = DB05721
| DrugBank = DB05721
| ChemSpiderID = 8061514
<!-- Chemical and physical data -->
<!-- Chemical and physical data -->
| IUPAC_name = 7-Chloro-3-[5-[(dimethylamino)methyl]-1,2,4-oxadiazol-3-yl]-5-methyl-4H-imidazo[1,5-a][1,4]benzodiazepin-6-one
| IUPAC_name = 7-Chloro-3-[5-[(dimethylamino)methyl]-1,2,4-oxadiazol-3-yl]-5-methyl-4''H''-imidazo[1,5-''a''][1,4]benzodiazepin-6-one
| C = 17 | H = 17 | Cl = 1 | N = 6 | O = 2
| C = 17 | H = 17 | Cl = 1 | N = 6 | O = 2
| smiles = Clc4cccc3n2cnc(c1nc(on1)CN(C)C)c2CN(C(=O)c34)C
| StdInChI = 1S/C17H17ClN6O2/c1-22(2)8-13-20-16(21-26-13)15-12-7-23(3)17(25)14-10(18)5-4-6-11(14)24(12)9-19-15/h4-6,9H,7-8H2,1-3H3
| StdInChIKey = JCYLWUVDHLVGER-UHFFFAOYSA-N
}}
}}


'''Dimdazenil''' (trade name '''Junoenil''') is a pharmaceutical drug for [[insomnia]].<ref>{{cite journal | doi = 10.1093/sleep/zsad272 | title = Efficacy and safety of Dimdazenil in adults with insomnia disorder: Results from a multicenter, randomized, double-blind, placebo-controlled phase III trials | date = 2024 | last1 = Huang | first1 = Zhaoyang | last2 = Zhan | first2 = Shuqin | last3 = Chen | first3 = Chunyan | last4 = Zhang | first4 = Ruoxi | last5 = Zhou | first5 = Yanling | last6 = He | first6 = Jingjing | last7 = Lin | first7 = Zhaocun | last8 = Bao | first8 = Cungang | last9 = Zhu | first9 = Shuangpeng | last10 = Zhao | first10 = Jianjun | last11 = Zhang | first11 = Shengan | last12 = Jiang | first12 = Yu | last13 = Wang | first13 = Yuping | journal = Sleep | volume = 47 | issue = 2 | pmid = 37875349 | pmc = 10851846 }}</ref>
'''Dimdazenil''' (trade name '''Junoenil''') is a pharmaceutical drug for [[insomnia]].<ref>{{cite journal | doi = 10.1093/sleep/zsad272 | title = Efficacy and safety of Dimdazenil in adults with insomnia disorder: Results from a multicenter, randomized, double-blind, placebo-controlled phase III trials | date = 2024 | last1 = Huang | first1 = Zhaoyang | last2 = Zhan | first2 = Shuqin | last3 = Chen | first3 = Chunyan | last4 = Zhang | first4 = Ruoxi | last5 = Zhou | first5 = Yanling | last6 = He | first6 = Jingjing | last7 = Lin | first7 = Zhaocun | last8 = Bao | first8 = Cungang | last9 = Zhu | first9 = Shuangpeng | last10 = Zhao | first10 = Jianjun | last11 = Zhang | first11 = Shengan | last12 = Jiang | first12 = Yu | last13 = Wang | first13 = Yuping | journal = Sleep | volume = 47 | issue = 2 | pmid = 37875349 | pmc = 10851846 }}</ref> It is a [[benzodiazepine]] [[chemical derivative|derivative]] and a partial [[GABAA receptor positive allosteric modulator|positive allosteric modulator of the GABA<sub>A</sub> receptor]]<ref name="Guilleminault2010">{{cite book| vauthors = Guilleminault C |title=Sleep Medicine|url=https://books.google.com/books?id=np1NaFTF_CQC&pg=PA574|year=2010|publisher=Elsevier Health Sciences|isbn=978-1-4377-1836-2|pages=574–}}</ref> with two- to four-fold higher functional [[affinity (pharmacology)|affinity]] for the [[GABRA1|α<sub>1</sub> subunit]] relative to the [[GABRA2|α<sub>2</sub>]], [[GABRA3|α<sub>3</sub>]], and [[GABRA5|α<sub>5</sub> subunit]]s.


==Medical use==
It is a partial [[GABAA receptor positive allosteric modulator|positive allosteric modulator of the GABA<sub>A</sub> receptor]] developed by Zhejiang Jingxin Pharmaceutical and [[Evotec]]. In China, dimdezenil is approved for short-term treatment of insomnia.<ref>{{cite journal | doi = 10.1007/s40265-024-02020-9 | title = Dimdazenil: First Approval | date = 2024 | last1 = Syed | first1 = Yahiya Y. | journal = Drugs | url = https://figshare.com/articles/online_resource/Dimdazenil_First_Approval/25355965 }}</ref>
Dimdezenil shows effectiveness in the treatment of [[insomnia]], but has less [[intrinsic activity]] in comparison to currently-marketed benzodiazepines and the [[Z-drug]]s;<ref name="MontiPandi-Perumal2010">{{cite book| vauthors = Monti JM, Pandi-Perumal SR, Möhler H |title=GABA and Sleep: Molecular, Functional and Clinical Aspects|url=https://books.google.com/books?id=u54tqIOP8RUC&pg=PA50|date=28 September 2010|publisher=Springer Science & Business Media|isbn=978-3-0346-0226-6|pages=50–51}}</ref> however, it is thought that the lower efficacy may result in fewer [[side effect]]s, such as [[motor incoordination]].<ref name="MontiPandi-Perumal2010" /> In China, dimdezenil is approved for short-term treatment of insomnia.<ref>{{cite journal | doi = 10.1007/s40265-024-02020-9 | title = Dimdazenil: First Approval | date = 2024 | last1 = Syed | first1 = Yahiya Y. | journal = Drugs | url = https://figshare.com/articles/online_resource/Dimdazenil_First_Approval/25355965 }}</ref>

==History==
Dimdezenil was originally developed by [[Hoffmann-La Roche|Roche]], based on [[preclinical]] data, as a non-[[sedation|sedating]] [[anxiolytic]], but was found to produce [[sedation]] in humans in [[Phases of clinical research#Phase I|phase I]] [[clinical trial]]s. For this reason, it was subsequently licensed to [[Evotec]], which is now developing it for the treatment of insomnia.<ref name="MontiPandi-Perumal2010" /> By 2007, dimdezenil completed [[Phases of clinical research#Phase II|phase II]] clinical trials for this indication, with positive findings reported.<ref name="Plunkett2007">{{cite book| vauthors = Plunkett JW |title=Plunkett's Biotech & Genetics Industry Almanac 2008: Biotech & Genetics Industry Market Research, Statistics, Trends & Leading Companies|url=https://books.google.com/books?id=3BGBibHJ1FYC&pg=PT311|date=September 2007|publisher=Plunkett Research, Ltd.|isbn=978-1-59392-087-6|pages=311–}}</ref> In China, the drug was developed by Zhejiang Jingxin Pharmaceutical.


==References==
==References==
{{reflist}}
{{reflist}}

==External links==
* [http://adisinsight.springer.com/drugs/800023883 Dimdazenil - AdisInsight]


{{GABAA receptor positive modulators}}
{{GABAA receptor positive modulators}}
Line 72: Line 84:
[[Category:Oxadiazoles]]
[[Category:Oxadiazoles]]
[[Category:Imidazobenzodiazepines]]
[[Category:Imidazobenzodiazepines]]
[[Category:Dimethylamino compounds]]

[[Category:Chloroarenes]]
{{nervous-system-drug-stub}}
[[Category:Hypnotics]]
[[Category:Sedatives]]

Revision as of 18:49, 18 April 2024

Dimdazenil
200px
Clinical data
Trade namesJunoenil
Other namesEVT-201
Legal status
Legal status
  • Rx in China
Identifiers
  • 7-Chloro-3-[5-[(dimethylamino)methyl]-1,2,4-oxadiazol-3-yl]-5-methyl-4H-imidazo[1,5-a][1,4]benzodiazepin-6-one
CAS Number
PubChem CID
DrugBank
ChemSpider
UNII
Chemical and physical data
FormulaC17H17ClN6O2
Molar mass372.81 g·mol−1
3D model (JSmol)
  • Clc4cccc3n2cnc(c1nc(on1)CN(C)C)c2CN(C(=O)c34)C
  • InChI=1S/C17H17ClN6O2/c1-22(2)8-13-20-16(21-26-13)15-12-7-23(3)17(25)14-10(18)5-4-6-11(14)24(12)9-19-15/h4-6,9H,7-8H2,1-3H3
  • Key:JCYLWUVDHLVGER-UHFFFAOYSA-N

Dimdazenil (trade name Junoenil) is a pharmaceutical drug for insomnia.[1] It is a benzodiazepine derivative and a partial positive allosteric modulator of the GABAA receptor[2] with two- to four-fold higher functional affinity for the α1 subunit relative to the α2, α3, and α5 subunits.

Medical use

Dimdezenil shows effectiveness in the treatment of insomnia, but has less intrinsic activity in comparison to currently-marketed benzodiazepines and the Z-drugs;[3] however, it is thought that the lower efficacy may result in fewer side effects, such as motor incoordination.[3] In China, dimdezenil is approved for short-term treatment of insomnia.[4]

History

Dimdezenil was originally developed by Roche, based on preclinical data, as a non-sedating anxiolytic, but was found to produce sedation in humans in phase I clinical trials. For this reason, it was subsequently licensed to Evotec, which is now developing it for the treatment of insomnia.[3] By 2007, dimdezenil completed phase II clinical trials for this indication, with positive findings reported.[5] In China, the drug was developed by Zhejiang Jingxin Pharmaceutical.

References

  1. ^ Huang, Zhaoyang; Zhan, Shuqin; Chen, Chunyan; Zhang, Ruoxi; Zhou, Yanling; He, Jingjing; Lin, Zhaocun; Bao, Cungang; Zhu, Shuangpeng; Zhao, Jianjun; Zhang, Shengan; Jiang, Yu; Wang, Yuping (2024). "Efficacy and safety of Dimdazenil in adults with insomnia disorder: Results from a multicenter, randomized, double-blind, placebo-controlled phase III trials". Sleep. 47 (2). doi:10.1093/sleep/zsad272. PMC 10851846. PMID 37875349.
  2. ^ Guilleminault C (2010). Sleep Medicine. Elsevier Health Sciences. pp. 574–. ISBN 978-1-4377-1836-2.
  3. ^ a b c Monti JM, Pandi-Perumal SR, Möhler H (28 September 2010). GABA and Sleep: Molecular, Functional and Clinical Aspects. Springer Science & Business Media. pp. 50–51. ISBN 978-3-0346-0226-6.
  4. ^ Syed, Yahiya Y. (2024). "Dimdazenil: First Approval". Drugs. doi:10.1007/s40265-024-02020-9.
  5. ^ Plunkett JW (September 2007). Plunkett's Biotech & Genetics Industry Almanac 2008: Biotech & Genetics Industry Market Research, Statistics, Trends & Leading Companies. Plunkett Research, Ltd. pp. 311–. ISBN 978-1-59392-087-6.

External links

Retrieved from "https://en.wikipedia.org/w/index.php?title=Dimdazenil&oldid=1219600738"